Comprehensive sequence analysis of the E1A proteins of human and simian adenoviruses  by Avvakumov, N. et al.
www.elsevier.com/locate/yviroVirology 329 (20Comprehensive sequence analysis of the E1A proteins of human
and simian adenoviruses
N. Avvakumova, A.E. Kajonb, R.C. Hoebenc, J.S. Mymryka,*
aDepartment of Microbiology and Immunology, London Regional Cancer Centre, The University of Western Ontario, London, Ontario, Canada, N6A 4L6
bLovelace Respiratory Research Institute, Albuquerque, NM, USA
cDepartment of Molecular Cell Biology, Leiden University Medical Centre, Leiden, The Netherlands
Received 25 May 2004; returned to author for revision 8 July 2004; accepted 9 August 2004Abstract
Despite extensive study of human adenovirus type 5 E1A, surprisingly little is known about the E1A proteins of other adenoviruses.
We report here a comprehensive analysis of the sequences of 34 E1A proteins. These represent all six primate adenovirus subgroups and
include all human representatives of subgroups A, C, E, and F, eight from subgroup B, nine from subgroup D, and seven simian
adenovirus E1A sequences. We observed that many, but not all, functional domains identified in human adenovirus type 5 E1A are
recognizably present in the other E1A proteins. Importantly, we identified highly conserved sequences without known activities or binding
partners, suggesting that previously unrecognized determinants of E1A function remain to be uncovered. Overall, our analysis forms a
solid foundation for future study of the activities and features of the E1A proteins of different serotypes and identifies new avenues for
investigating E1A function.
D 2004 Elsevier Inc. All rights reserved.Introduction
To date, 51 human adenovirus (HAdV) serotypes have
been isolated and these have been divided into six
subgroups, termed A–F, according to a variety of criteria
(Benko¨ et al., 2000). In primate adenoviruses, Early Region
1A (E1A) is the first gene expressed after infection of the
host cell (Nevins et al., 1979). It has been most extensively
characterized in subgroup C HAdV type five (HAdV-5) and
HAdV-2, which are virtually identical in sequence and will
be treated as interchangeable in this report. In these viruses,
E1A encodes two major proteins of 289 and 243 amino acid
residues (R), which differ only by the presence of 46
additional amino acids in the larger protein as a result of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: jmymryk@uwo.ca (J.S. Mymryk).differential splicing of the primary RNA transcript (Perri-
caudet et al., 1979). The E1A proteins are localized in
roughly equal amounts in both the cytoplasm and nucleus
(Rowe et al., 1983; Turnell et al., 2000). Three additional
mRNA species are produced at later times that encode, or
are predicted to encode, E1A proteins of 217, 171, and 55R
(Stephens and Harlow, 1987; Ulfendahl et al., 1987). The
E1A proteins of HAdV-12 from subgroup A have been
studied less extensively, but appear at least superficially
similar to those of HAdV-5. For example, the E1A gene of
HAdV-12 encodes two major proteins of 266 and 235R that
share homology with the HAdV-5 289 and 243R E1A
proteins (Perricaudet et al., 1980), as well as several minor
species (Sawada and Fujinaga, 1980; Brockmann et al.,
1990). The E1A proteins of HAdV-5 and HAdV-12 appear
more or less functionally equivalent as they activate
expression of other viral early genes and reprogram cell
growth to provide an optimal environment for viral
replication (Bayley and Mymryk, 1994; Boulanger and
Blair, 1991; Dyson and Harlow, 1992; Frisch and Mymryk,
2002; Gallimore and Turnell, 2001; Moran, 1994; Peeper04) 477–492
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make them both essential for a productive infection by their
respective viruses (Byrd et al., 1988; Jones and Shenk,
1979).
HAdV-5 and HAdV-12 E1A proteins interact with a
variety of cellular proteins, including transcriptional co-
activators such as the CREB-binding protein (CBP) and
p300 (Arany et al., 1995; Dorsman et al., 1997; Eckner et
al., 1994; Jelinek and Graham, 1992; Lundblad et al., 1995;
Sawada et al., 1997; Wang et al., 1993b), the p300/CBP
Associated Factor (pCAF) (Reid et al., 1998; Shuen et al.,
2003), and the transcriptional co-repressors CtBP (Grand et
al., 1998; Schaeper et al., 1995) and BS69 (Ansieau and
Leutz, 2002; Hateboer et al., 1995). Similarly, E1A proteins
from both viruses interact with the TATA-binding protein
(TBP) component of the general transcriptional machinery
(Boyer and Berk, 1993; Geisberg et al., 1994; Grand et al.,
1998; Hateboer et al., 1993; Horikoshi et al., 1991; Song et
al., 1995). In addition, both HAdV-5 and HAdV-12 E1A
proteins directly target the retinoblastoma tumor suppressor
gene product (Rb) and related family members p130 and
p107 (Egan et al., 1989; Ewen et al., 1991; Hannon et al.,
1993; Jelinek and Graham, 1992; Peeper et al., 1992; Whyte
et al., 1988), and the cyclin-dependent kinase inhibitor p27
(Mal et al., 1996b; Nomura et al., 1998) that regulates the
cell division cycle. HAdV-5 and HAdV-12 also bind the
SUMO conjugase UBC9 (Hateboer et al., 1996) and
proteasome components (Grand et al., 1999; Turnell et al.,
2000). Because of these many interactions with cellular
regulatory proteins, the multifunctional E1A proteins
influence a wide variety of transcriptional and cell cycle
events (Bayley and Mymryk, 1994; Dyson and Harlow,
1992; Gallimore and Turnell, 2001; Moran, 1994; Peeper
and Zantema, 1993; Shenk and Flint, 1991). Importantly,
the E1A genes of many different HAdVs, including HAdV-5
and HAdV-12 function as oncogenes in cultured rodent cells
(Bayley and Mymryk, 1994; Endter and Dobner, 2004;
Gallimore and Turnell, 2001). However, the ability of these
transformed cells to induce tumors in animals varies greatly
depending on the species of E1A used (Endter and Dobner,
2004; Gallimore and Turnell, 2001; Huebner et al., 1962;
Trentin et al., 1962; Williams et al., 1995). Intriguingly,
HAdV-5 E1A, which is classified as non-oncogenic in
rodent systems, has been shown to function as a tumor
suppressor gene by inhibiting tumorigenesis and metastasis
(Frisch and Mymryk, 2002; Mymryk, 1996) and may have
some utility in cancer therapy (Ueno et al., 2001).
Despite the large number of studies focusing on HAdV-5
E1A, relatively little is known about the function of the E1A
proteins of other adenoviruses, including HAdV-12. This
raises questions regarding how representative HAdV-5 E1A
is of the other E1A proteins. It seems unlikely that each of
the different proteins performs identical functions. For
example, in addition to significant differences between the
tumorigenic effects of HAdV-5 and HAdV-12 E1A pointed
out above, HAdV-12 E1A but not HAdV-5 E1A repressesmajor histocompatibility complex class I transcription in the
infected cell (Ackrill and Blair, 1988; Bernards et al., 1983;
Friedman and Ricciardi, 1988). The two proteins have
differential effects on expression of the junB and junD genes
(de Groot et al., 1991), and the N-terminus of HAdV-12
E1A harbors a trans-activation function not detectable in
HAdV-5 E1A (Lipinski et al., 1997). Despite these known
differences, and potentially many more yet to be identified,
the E1 regions of subgroup A, B, C, and E viruses can
complement an E1-defective HAdV-5 virus for growth in
culture, suggesting that at least key functions are conserved
(Rademaker et al., 2002).
Previous comparisons of E1A sequences from human
and simian adenoviruses (SAdVs) identified four regions of
high sequence homology designated conserved regions
(CR) 1, 2, 3, and 4 (Avvakumov et al., 2002b; Kimelman
et al., 1985). As expected from their strong conservation,
these regions are critical for many activities of E1A (Bayley
and Mymryk, 1994; Frisch and Mymryk, 2002; Gallimore
and Turnell, 2001).
We report here a comprehensive comparison of the
sequences of 34 E1A proteins. Many functional domains
identified in human adenovirus type 5 E1A are recognizably
conserved among the other E1A proteins. However, we
identify highly conserved sequences without known activ-
ities or binding partners, providing new avenues to discover
novel E1A targets and functions. Our analysis also forms a
solid foundation from which study of the activities and
features of other E1A proteins can begin.Results and discussion
We report here the sequences of the E1A genes of HAdV
types 1, 6, 8, 14, 16, 18, 23, 28, and 31. These were
determined as described previously (Avvakumov et al.,
2002b), and their GenBank accession numbers are listed in
Table 1. Combining these with the newly available E1A
sequences from HAdV-11, 26, 35, 36, 49, and 51 and
SAdV-21 through 24, we report here a comprehensive
comparison of the predicted sequences of thirty-four E1A
proteins. These include all human representatives of
subgroups A, C, E, and F, eight from subgroup B and nine
from subgroup D, as well as seven SAdV E1A sequences.
These proteins range in size from 249 to 289 residues, with
the subgroup C proteins being the largest and the subgroup
D and F proteins the smallest.
The organization of the E1A sequences into six
subgroups is displayed as an unrooted phylogenetic tree
(Fig. 1). The most commonly accepted source of phyloge-
netic information for the AdV is the hexon sequence and our
subgroup assignations agree with current designations for
those AdV with known hexon sequence (Benko¨ et al.,
2000). It is also clear from our analysis that there is little, if
any, distinction between most of the currently known human
and simian AdV E1A sequences. Indeed, virus neutraliza-
Fig. 1. Phylogenetic tree for the adenovirus E1A proteins. An unrooted tree
was generated for the E1A proteins based on sequence alignment with the
PHYLIP and TreeView programs as described in Materials and methods.
Branch length is proportional to genetic distance. Each species of E1A is
labeled at the tip of its representative branch. The adenoviral subgroups are
labeled as A–F according to convention. Some regions are enlarged by the
indicated magnification factor for better visualization.
Table 1
Genbank accession numbers, subgroup classification and size of the largest
E1A protein products of human and simian adenoviruses
Virus Accession no. Subgroup E1A
size
(aa)a
Sourceb
HAdV-1 AAS65966 C 289 LUMC-MCBc
HAdV-2 P03254 C 289 –
HAdV-3 AAM46821 B:1 261 –
HAdV-4 P10407 E 257 –
HAdV-5 P03255 C 289 –
HAdV-6 AAS65967 C 289 CDCd
HAdV-7i P03256 B:1 261 –
HAdV-7ii AAA42455 B:1 261 –
HAdV-8 AAS65968 D 253 ATCCe
HAdV-9 AAD16301 D 251 –
HAdV-11 AAN62486 B:2 262 –
HAdV-12 P03259 A 266 –
HAdV-14 AAS65969 B:2 261 ATCC
HAdV-16 AAS65970 B:1 261 ATCC
HAdV-17 AF108105 D 253 –
HAdV-18 AAS65971 A 278 ATCC
HAdV-21 AAM46822 B:1 261 –
HAdV-23 AAS65972 D 253 ATCC
HAdV-26 AY678272 D 251 Crucellf
HAdV-28 AAS65973 D 253 ATCC
HAdV-31 AAS65974 A 265 CDC
HAdV-35 AX049983 B:2 262 –
HAdV-36 AAQ72377 D 253 –
HAdV-40 P10541 F 249 –
HAdV-41 P10542 F 251 –
HAdV-49 AY678273 D 253 Crucell
HAdV-51 AY678274 D 253 Crucell
SAdV-7i P06499 A 266 –
SAdV-7ii CAA25511 A 266 –
SAdV-21 DAA00791 B 262 –
SAdV-22 AAS10355 E 258 –
SAdV-23 AAS10391 E 258 –
SAdV-24 AAS10427 E 258 –
SAdV-25 AAL35510 E 257 –
a aa, amino acids.
b Listed only for newly determined sequences.
c Leiden University Medical Centre, Department of Molecular Cell
Biology virus collection.
d Centers for disease control and prevention.
e American Type Culture Collection.
f Sequence obtained from Crucell, Leiden, The Netherlands before
Genbank submission.
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are related to HAdV (Wigand et al., 1989; Willimzik et al.,
1981). Of the sequences analyzed here, those within
subgroup C are the most closely related. This suggests that
these viruses evolved together to infect a specific subset of
target cells and that genetic divergence is not well tolerated.
Subgroup B is clearly composed of two distinct subsets,
which corresponds well with their phylogenetic classifica-
tion as B:1 and B:2 (Benko¨ et al., 2000). Interestingly,
SAdV-21 E1A is intermediate between these two subsets.
Subgroup D contains two viruses-HAdV-23 and HAdV-51-
whose E1A protein, though not nucleotide, sequences are
identical. Of note, the SAdV-7 sequences are highlydivergent from the subgroup A HAdV sequences, suggest-
ing that they could be classified as a distinct subset, as
previously done with the subgroup B viruses, or possibly
even be considered to represent a seventh subgroup.
However, alternative classification of SAdV-7 must await
the determination of its hexon sequence.
We noticed a duplication of sequence in HAdV-18 E1A
between CR1 and CR2 (Fig. 2). The duplicate sequences are
ATSEGLLLTEPPVISPV and AASDGLLLTDPPILSPV,
which are clearly recognizable despite evident divergence.
This duplication was observed in HAdV-18 obtained from
the ATCC and CDC, and nearly doubles the distance
between CR1 and CR2 in this protein. A short duplication
of the residues QPE is also apparent in the subgroup C E1A
proteins in the same general region (Fig. 2).
Refining the conserved regions of E1A
Alignment of the 34 E1A sequences (Figs. 2 and 3) did
not alter the boundaries of CR1 and CR3, which remain at
alignment position (a.p.) 50–81 and 199–246, respectively.
Within CR3, the four cysteine residues that form the zinc
finger (Culp et al., 1988) are absolutely conserved at
alignment positions 209, 212, 226, and 229. The boundaries
Fig. 2. Alignment of the N-terminal sequences of adenovirus E1A proteins. Sequences were aligned as described in Materials and methods and
shaded for conservation. Darker shading corresponds to higher levels of conservation. Gaps are indicated as dots. Arrowheads indicate highly conserved
residues (N60% similarity) without known function. The positions of the conserved regions (CR) are indicated as black bars. Numbers at the end of each row
indicate the last residue’s position within the particular sequence. The binding sites for CBP, Rb and BS69, as well as the conserved phosphorylation site are
indicated.
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incorporation of the additional 19 sequences into the current
analysis has allowed us to identify substantially greater
conservation within the C-terminus of the E1A proteins.
This expands CR4 to encompass a.p. 296–353, with anoverall relative similarity between the different E1A
proteins of 60%. CR4 is clearly composed of two discrete
regions of higher conservation, with an intervening less
conserved sequence that is generally acidic and often
glycine-rich.
Fig. 3. Alignment of the C-terminal sequences of adenovirus E1A proteins. The sequences of the indicated adenovirus E1A proteins were aligned and labeled
as described in the legend to Fig. 2. The zinc-finger, auxiliary region 1 (AR1), the binding site for CtBP, the canonical monopartite nuclear localization
sequence (NLS), and the conserved phosphorylation sites are indicated.
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E1A types
We examined whether known binding sites for E1A
interacting proteins, sites of covalent modification, and
well-characterized functional motifs were conserved amongour expanded collection of HAdV and SAdV E1A
proteins.
Rb interaction sites
HAdV-5 E1A makes two separate contacts with Rb
(Dyson et al., 1992). The major interaction requires the
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of E1A (Dyson et al., 1989). This motif is absolutely
conserved in all the E1A sequences (Fig. 2, a.p. 150, 152,
and 154), underscoring the importance of this interaction for
viral activation of cell cycle progression and transcription
(Bayley and Mymryk, 1994). In all the E1A proteins, an
invariant aspartic acid residue precedes this consensus site,
suggesting that they all bind Rb with high affinity (Heck et
al., 1992).
The crystal structure of the relevant portion of Rb with a
peptide corresponding to the orthologous LXCXE sequence
from the human papillomavirus 16 E7 protein indicates that
each key residue of the motif fits tightly, making a high
density of contacts in a shallow groove on the surface of Rb
that ensures specificity (Lee et al., 1998). An additional
leucine positioned two residues after the LXCXE motif in E7
interacts with a hydrophobic pocket on Rb, but the broader
nature of this pocket likely allows some flexibility in the
identity and position of this residue. Based on this structure,
it was suggested that the corresponding contact in HAdV-5
E1A is the phenylalanine at position 129 (a.p. 157), which is
located three residues after the motif. All the E1A proteins
contain a hydrophobic residue at this position, suggesting
that this somewhat less specific contact with Rb is
maintained. The crystal structure also suggests that a patch
of six basic residues on the rim of the LXCXE-binding
groove in Rb could interact with the acidic residues present
in E7 after the LXCXE motif, although these were not
present in the E7 peptide used for the crystal structure (Lee et
al., 1998). It was later confirmed that conversion of these
residues in Rb from basic to acidic reduces or abolishes
interaction of E7 or SV40 large T antigen, which also
contains an LXCXE motif followed by a string of acidic
residues (Brown and Gallie, 2002; Dick and Dyson, 2002).
E7 binding to such an Rb mutant was restored by converting
the acid residues following the LXCXE motif in E7 to basic
residues, further demonstrating the necessity for this ionic
interaction (Dick and Dyson, 2002). Like in E7 and large T
antigen, a similar string of acidic residues following the
LXCXE motif is present in all the different E1A proteins
(Fig. 2, a.p. 161–169). However, mutational analysis of
HAdV-5 and HAdV-12 E1A has not consistently shown a
requirement for these residues for Rb binding (Alevizopou-
los et al., 2000; Barbeau et al., 1994; Putzer et al., 1997).
In addition to mutations in the LXCXE motif, deletions
within residues 30–60 were shown to impair the ability of
HAdV-5 E1A to co-immunoprecipitate Rb (Egan et al.,
1988; Wang et al., 1991; Whyte et al., 1989). Mutations in
this region also blocked the ability of HAdV-5 E1A to
dissociate Rb from E2F transcription factors (Raychaudhuri
et al., 1991). This led to the identification of a second region
of HAdV-5 E1A, spanning residues 37–54 (a.p. 44–63),
which can independently interact with Rb, but with a greatly
lower affinity (Dyson et al., 1992). This second Rb-binding
site of E1A competes with E2F for interaction with Rb, and
in combination with CR2 disrupts Rb–E2F complexes(Ikeda and Nevins, 1993). Indeed, deletion of residues 38–
44 of HAdV-5 E1A, which comprise the N-terminal edge of
CR1, abrogates interaction with Rb (Wong and Ziff, 1994).
Interestingly, while the tyrosine at position 47 (a.p. 55) is
also important for interaction with Rb, the neighboring
highly conserved leucine at position 49 (a.p. 57) is not
(Wang et al., 1993a). Taken together, these studies suggest
that the interaction domain maps mainly between residues
37 and 47 of HAdV-5 E1A (a.p. 44–55), although additional
residues are likely required as deletion of residues 48–60
(a.p. 56–69) also impairs binding (Barbeau et al., 1994;
Egan et al., 1988). As currently defined, the second Rb
interaction site overlaps the N-terminal boundary of CR1,
which is absolutely conserved in all the E1A proteins with
the exception of HAdV-41 (Fig. 2). Given the high degree of
conservation of this region, its ability to mediate an
interaction with Rb is probably a common feature of all
E1A proteins. However, it is intriguing that mutation of the
highly conserved leucine 49 (a.p. 57) to proline does not
affect interaction with Rb, nor any other known function of
HAdV-5 E1A (Wang et al., 1993a). Thus, the reason for its
conservation, and refinement of the determinants for Rb
interaction remain promising areas of investigation.
p300–CBP interaction sites
Similarly to its interaction with Rb, HAdV-5 E1A makes
several distinct contacts with portions of the transcriptional
co-activators CREB-binding protein (CBP) and the related
p300 protein (Arany et al., 1995; Eckner et al., 1994;
Kurokawa et al., 1998), as does HAdV-12 E1A (Fax et al.,
2000; Lipinski et al., 1999). The FXE/DXXXL consensus
sequence located within CR1 of HAdV-2, -5, and -12 E1A
interacts with the TRAM motif of CBP, located within the
CH3 region (O’Connor et al., 1999). Small deletions within
this region of HAdV-5 E1A block co-precipitation of p300/
CBP (Barbeau et al., 1994; Mymryk et al., 1992; Wong and
Ziff, 1994). Similarly, substitution of an alanine, but not
aspartic acid, for the glutamic acid at the third position of
the motif blocks the ability of HAdV-12 E1A to bind p300/
CBP (Sawada et al., 1997). With the exception of HAdV-41,
the key positions within this motif are well conserved in all
sequences (Fig. 2, a.p. 75, 77, 81). This is in agreement with
our observation that representative E1A proteins from all six
subgroups bind CBP (Shuen et al., 2003). In addition,
mutation of the arginine at position 2 to glycine or the
histidine at position 3 to asparagine disrupts or seriously
reduces the ability of HAdV-5 E1A to co-precipitate full-
length p300/CBP from human HeLa cells (Wang et al.,
1993a; Whyte et al., 1989). Mutation of the histidine at
position 3 or deletion of residues 6–10 in HAdV-5 E1A (a.p.
9–14) also specifically reduces interaction with the CH3
region of CBP or p300 (Boyd et al., 2002; Kurokawa et al.,
1998). These results suggest that the extreme N-terminal
portion of HAdV-5 E1A functions in concert with the
TRAM-binding region described above to contact the CH3
region of p300/CBP. While the arginine at position 2 is
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histidine at position 3 is not. This suggests that interaction
between the N-terminal portions of the different E1A
proteins and the CH3 region of p300/CBP are not precisely
the same. This is substantiated by the observation that the
arginine at position 2 in HAdV-12 E1A is not required for
binding to p300, although it is in HAdV-5 E1A (Lipinski et
al., 1999).
In addition to interacting with the CH3 region of p300/
CBP, the HAdV-5 and -12 E1A proteins bind to the C-
terminal portion of CBP spanning residues 2067–2112
(Kurokawa et al., 1998; Lin et al., 2001; Lipinski et al.,
1999). This region of CBP is also bound by several cellular
transcription factors, including IRF-3, Ets-2, p53, and
members of the NCoA/p160 family, and HAdV-5 E1A
can compete with at least some of these for this interaction
(Kamei et al., 1996; Lin et al., 2001; Livengood et al., 2002;
Matsuda et al., 2004). The extreme N-terminus of HAdV-5
E1A is not required for this interaction, as mutation of the
histidine at position 3 does not affect binding (Kurokawa et
al., 1998; Lin et al., 2001). The solution structure of this
region of CBP complexed with the AD1 region of ACTR,
an NCoA/p160 protein, shows that these domains undergo
mutual synergistic folding to form a helical heterodimer
(Demarest et al., 2002). Sequence alignment of E1A with
ACTR and other cellular proteins that bind this region of
CBP demonstrates that they all possess limited sequence
homology, largely composed of a putative amphipathic a-
helix (Matsuda et al., 2004). In HAdV-5 E1A, this region
spans residues 19–28 (LLDQLIEEVL, a.p. 23–32) and is
located within the relatively non-conserved N-terminus. Our
analysis indicates that the second leucine in this motif is
absolutely conserved in all the different E1A proteins.
Mutation of this leucine, but not the adjacent aspartic acid to
alanine, in HAdV-5 E1A greatly reduces its ability to co-
precipitate full-length p300/CBP from human HeLa cells,
further supporting a role for this region in interaction with
p300/CBP (Wang et al., 1993a). In addition, deletion of
residues 20–24 of HAdV-5 E1A (a.p. 24–28) abolishes co-
precipitation of p300/CBP (Wong and Ziff, 1994).
Sequences closely resembling this putative a-helix
consensus motif are present in all the subgroup B and C
E1A proteins (Fig. 2). Ets-2 and the NCoA/p160 protein
SRC-1 contain phenylalanine or tryptophan at key positions
in this CBP interaction motif, suggesting that these residues
may functionally substitute for leucine in this interaction
(Matsuda et al., 2004). Intriguingly, variants of this motif
containing phenylalanine in place of leucine are usually
present in subgroup A and D proteins and more divergent
sequences resembling this motif are present closer to the N-
terminus of SAdV-7, HAdV-40, and 41. Phenylalanine at
the terminal position of this motif likely maintains
interaction, as deletion of residues 26–35 in HAdV-5 E1A
(a.p. 30–39), which removes the C-terminal portion of the
motif, but brings phenylalanine 38 (a.p. 45) into place, still
efficiently co-precipitates p300/CBP (Barbeau et al., 1994;Egan et al., 1988). Overall, the consensus motif in the
various E1A proteins is CCXXCCXXCC (where C is
generally I, L, V, M, or F). It seems highly likely that even
divergent variants of this motif, such as that found in HAdV-
12 E1A (ILEHLVDNFF), confer functional interaction with
the C-terminal portion of p300/CBP as mutation of the first
two residues of this motif in HAdV-12 E1A severely
reduces binding to p300/CBP (Fax et al., 2000; Lipinski
et al., 1999). However, additional mutational studies will be
necessary to confirm a role for this region in the interaction
of the different E1A proteins with the C-terminal portion of
CBP.
CtBP interaction site
The interaction of the transcriptional co-repressor CtBP
with HAdV-5 and HAdV-12 E1A requires the sequence
PLDLS near the C-terminus within CR4 (Molloy et al.,
1998; Schaeper et al., 1995). Deletion of residues 239–254
reduces the interaction of HAdV-5 E1Awith CtBP (Boyd et
al., 1993; Schaeper et al., 1995; Zhang et al., 2001), and
these sequences correspond to the N-terminal portion of
CR4 (a.p. 295–311). The role of the remaining portion of
CR4 remains unknown.
The PLDLS motif or homologous variants are present in
all E1A types with the exception of the proteins of SAdV-21
and the subgroup E viruses, which contain the variant
PLDLC. Intriguingly, this substitution was isolated as a
naturally occurring mutation in the PLDLS motif of human
homeodomain protein TGIF, which results in a develop-
mental defect called holoprosencephaly (Gripp et al., 2000).
In TGIF, this mutation blocks interaction with CtBP and
impairs transcriptional repression (Melhuish and Wotton,
2000). Thus, CtBP is probably not targeted by the E1A
proteins of SAdV-21 or the subgroup E viruses, most of
which are simian in origin as well. This differential
requirement for CtBP interaction will likely prove an
interesting area of future investigation.
An adjacent lysine residue is present within one or two
residues of the CtBP-binding motif in all thirty-four E1A
sequences. Acetylation of this lysine in HAdV-5 E1A by
p300 or pCAF may block interaction with CtBP (Zhang et
al., 2000), but this has not been confirmed (Madison et al.,
2002).
BS69 interaction site
The transcriptional co-repressor and potential tumor
suppressor BS69 has been demonstrated to bind the PXLXP
motif present in cellular and viral proteins including E1A
(Ansieau and Leutz, 2002). This sequence is located
immediately upstream of CR2 in HAdV-5 E1A, but appears
to be weakly conserved across the various adenovirus
species. It remains to be determined whether this interaction
is specific to a subset of E1A proteins. The CR3 region of
HAdV-5 E1A also independently binds BS69 (Hateboer et
al., 1995). The consequences of the E1A–BS69 interaction
remain to be elucidated, although overexpression of BS69
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TBP interaction sites
As seen with Rb or p300/CBP, two separate regions of
E1A contact the TBP component of the general transcription
factor IID. The N-terminal portions of HAdV-5 and -12 E1A
each interact with TBP in vitro, and this binding maps
within the first 29 residues of each protein (Lipinski et al.,
1998; Song et al., 1995, 1997). Detailed mapping of the
interaction of HAdV-5 E1A with TBP indicates that the
most critical contact is the cysteine at position 6 (a.p. 9)
(Boyd et al., 2002), which is present only in the subgroup C
E1A proteins. Despite the absence of a cysteine in a
comparable position in the N-terminal portion of HAdV-12
E1A, the first 29 residues of HAdV-12 E1A bind TBP
(Lipinski et al., 1998). It is thought that the interaction of the
N-terminal portion of HAdV-5 E1Awith TBP contributes to
transcriptional repression by dissociating TBP from the
TATA box (Boyd et al., 2002; Song et al., 1995, 1997).
However, additional studies will be required to define the
contacts before any generalizations can be made regarding
the potential ability of the other E1A proteins to perform
this activity.
In addition to the N-terminal interaction site, CR3 of
HAdV-5 E1A independently targets TBP as part of the
mechanism by which it activates transcription (Boyer and
Berk, 1993; Lee et al., 1991). Binding has been mapped to
specific residues within the zinc-finger portion of CR3 in
exquisite detail (Geisberg et al., 1994) and will be discussed
further in the transcriptional activation section below.
Proteasome interaction sites
Both the HAdV-5 and HAdV-12 E1A proteins have
been shown to interact with the Sug1 (S8) ATPase
component of the 19S regulatory complex of the protea-
some (Grand et al., 1999). This interaction requires a region
in HAdV-5 E1A spanning residues 4–25 (a.p. 4–29), which
also makes an independent contact with the S4 ATPase of
the 19S regulatory complex (Turnell et al., 2000). Based on
the low level of homology between this region of HAdV-5
and -12, it is entirely possible that this interaction is
maintained in the other less characterized E1A proteins. An
additional interaction with the proteasome is mediated by
the region spanning residues 111–127 of HAdV-5 E1A
(a.p. 137–155), which overlaps the N-terminal boundary of
CR2 and contacts the non-ATPase S2 component of the
19S regulatory complex (Zhang et al., 2004). Given the
high level of sequence conservation in this region, it seem
likely that S2 represents a common target of the E1A
family of proteins.
Nuclear import signals
HAdV-5 contains an NLS at its carboxyl terminus,
composed of the sequence KRPRP (Lyons et al., 1987),
which is preferentially recognized by importin-a3 (Kohleret al., 2001) and does not function in growth-arrested cells
(Lyons, 1991). This motif is representative of a canonical
monopartite NLS, which is typified by the presence of four
adjacent basic residues, or three basic residues in combina-
tion with proline (Macara, 2001). With the exception of
SAdV-7 and -21 and the subgroup B:2, all E1A proteins
contain predicted canonical monopartite NLS near their C-
termini (Fig. 3, a.p. 350–355), suggesting that nuclear
localization via the carboxyl end is a property common to
most E1As. Whether these are preferentially targeted by
importin-a3 remains to be determined. Acetylation of lysine
285 within the C-terminal NLS of HAdV-5 E1A (a.p. 350)
by CBP blocks interaction with importin-a3 and is
associated with retention of the smaller 243R E1A protein
in the cytoplasm (Madison et al., 2002). Thus, subcellular
localization of the HAdV-5 E1A 243R protein may be
regulated by covalent modification. By extension, a similar
regulatory mechanism may exist for the smaller E1A
proteins of other serotypes. In addition to the C-terminal
NLS, a non-conventional NLS with the consensus sequence
FV(X)7–20MXSLXYM(X)4MF has been identified within
CR3 of HAdV-5, which is unique to the larger 289R protein
(Slavicek et al., 1989; Standiford and Richter, 1992). This
signal functions in a developmentally regulated fashion
(Standiford and Richter, 1992) and its presence in the 289R
E1A protein can confer nuclear localization irrespective of
the acetylation state of the C-terminal NLS (Madison et al.,
2002). Some of the key residues of the CR3 NLS are not
well conserved in other E1A proteins (Fig. 3, a.p. 197, 198,
225, 227, 228, 230, 231, 236, and 237), suggesting that this
function may be unique to certain adenoviral species.
Phosphorylation sites
Both HAdV-5 and HAdV-12 E1A proteins are exten-
sively phosphorylated at multiple serines mapped to
positions 89, 96, 132, 185, 188, and 219 in HAdV-5 E1A
(Dumont and Branton, 1992; Dumont et al., 1989, 1993;
Lucher et al., 1985; Richter et al., 1988; Smith et al., 1989;
Tremblay et al., 1989; Tsukamoto et al., 1986; Whalen et al.,
1997). Only serines 132, 185, and 188 (a.p. 160, 240 and
243) are conserved, and they are absolutely invariant in all
the E1A sequences. Interestingly, these are also the only
three phosphorylation sites within HAdV-5 E1A that are
known to affect its biological function. For example,
phosphorylation of HAdV-5 E1A serine 132 (a.p. 160),
which is adjacent to the LXCXE motif, enhances binding to
Rb (Whalen et al., 1996), and may increase its ability to
disrupt Rb–E2F complexes (Mal et al., 1996a). In all the
different E1A proteins, this site also conforms to a
consensus casein kinase II site (S/TXXD/E), and in
HAdV-5, this site is phosphorylated by this kinase in vitro
(Whalen et al., 1996). Similarly, phosphorylation of serines
185 and 188 (a.p. 240 and 243) in HAdV-5 E1A specifically
increases transcription of the E4 gene (Whalen et al., 1997).
Given the absolute conservation of these residues and their
adjacent sequence, it seems likely that phosphorylation of
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effects.
Transcriptional activation by E1A
HAdV-5 E1A strongly activates transcription of viral and
cellular genes (Bayley and Mymryk, 1994; Berk et al.,
1979; Brockmann and Esche, 2003; Jones and Shenk, 1979;
Shenk and Flint, 1991). Two major activities reside within
the N-terminal/CR1 and CR3 regions of E1A (Akusjarvi,
1993; Bayley and Mymryk, 1994; Brockmann and Esche,
2003; Shenk and Flint, 1991). It is currently thought that
recruitment of these transcriptional activation surfaces of
E1A to target genes occurs through interaction with
sequence specific DNA-binding factors, as HAdV-5 E1A
does not bind DNA specifically (Avvakumov et al., 2002a;
Chatterjee et al., 1988; Zu et al., 1992).
When fused to the Gal4p DBD, a transcriptional
activation region in HAdV-5 E1A has been identified that
overlaps CR1, located within residues 28–82 (a.p. 32–91)
(Bondesson et al., 1994; Shuen et al., 2002). A similar
activity also resides within CR1 of HAdV-12 E1A (Lipinski
et al., 1997). The strong conservation of sequence within
CR1 suggests that all E1A proteins contain a transcriptional
activation surface in this region. In support of this, we have
shown that the N-terminal/CR1 portions of HAdV-3, 4, 9,
12, and 40 all interact with the transcriptional co-activators
CBP, p300, and pCAF (Shuen et al., 2003), as previously
shown for HAdV-5 E1A.
When fused to the Gal4p DBD, a second transcriptional
activation domain of HAdV-5 E1A was identified within
residues 139–223 (a.p. 168–279) (Lillie and Green, 1989),
which encompass CR3. This region had already been known
to be critical for activation of viral early gene expression
(Glenn and Ricciardi, 1985; Jelsma et al., 1988; Lillie et al.,
1986; Moran et al., 1986; Schneider et al., 1987; Svensson
and Akusjarvi, 1984), but this observation provided a new
approach for detailed study of the mechanism of transcrip-
tional activation. Deletion analysis indicated that the N-
terminal boundary of this transcriptional activation region
maps to residues 141/142 (a.p. 195/197) (Martin et al.,
1990). In HAdV-5 E1A, the C-terminal boundary was
originally placed at residue 188 (a.p. 243), as a peptide
corresponding only to residues 140–188 (a.p. 169–243) is
sufficient to at least partially activate some viral early gene
expression during infection with a virus lacking E1A (Lillie
et al., 1987). Later work showed that two auxiliary regions
(AR), named AR1 and 2, encoded within exon 2 of HAdV-5
E1A are interchangeably required for efficient transcrip-
tional activation of the adenovirus E4 promoter (Bondesson
et al., 1992). AR1 maps between residues 189 and 200,
while AR2 maps between residues 224 and 245 in HAdV-5
E1A (a.p. 244–256 and 280–301, respectively). Further
analysis demonstrated that AR2 can only substitute for AR1
when artificially juxtaposed to CR3 (Strom et al., 1998).
The negative charge present within AR1, but not the exactprotein sequence, is critically important for E1A mediated
transcriptional activation of five different adenovirus early
promoters, as well as that of cellular HSP70. This suggests
that AR1 should be regarded as an integral part of the CR3
transactivation domain (Strom et al., 1998).
The alignment of the thirty-four E1A sequences demon-
strates that CR3 is very highly conserved. This is expected
given the critical role of this region in the activation of viral
transcription (Bayley and Mymryk, 1994; Shenk and Flint,
1991). Although the six repeats of glutamic acid-proline
found in AR1 of HAdV-5 E1A are not highly conserved,
most of the other E1A proteins have several acidic residues
within the corresponding region. In addition, many have a
preponderance of serine or threonine residues, which could
potentially contribute negative charge upon phosphoryla-
tion. This overall conservation of negative charge agrees
with the demonstration that it is the acidic character of this
region, rather than the exact sequence that is critical for
transcriptional activation (Strom et al., 1998). Conversely,
little conservation in the AR2 region is apparent, except for
small isolated blocks of sequence. This lack of conservation
coincides with the observation that this region is not
normally required for transactivation (Strom et al., 1998).
Transcriptional activation by the CR3 region of HAdV-5
E1A has been analyzed extensively using site-directed
mutagenesis (Fahnestock and Lewis, 1989; Lillie et al.,
1986; Jelsma et al., 1988; Martin et al., 1990; Webster and
Ricciardi, 1991). Indeed, every residue from 137 to 190 of
HAdV-5 E1A (a.p. 166–245) has been individually mutated
to at least one other amino acid. Studies of these mutants
have identified the key residues necessary for function and
produced a detailed understanding of the mechanism of
transcriptional activation by CR3. We have taken advantage
of this large body of data and used it to determine if the key
residues within CR3 that are required for transcriptional
activation by HAdV-5 E1A are conserved within the E1A
proteins of the other virus types (Fig. 4). We calculated the
frequency of amino acid conservation at each position in the
CR3 alignment of all non-subgroup C E1A proteins with
respect to HAdV-5 E1A. This was compared to residues
critical for transcriptional activation by HAdV-5 E1A, as
identified by point-mutation studies (Lillie et al., 1986;
Jelsma et al., 1988; Martin et al., 1990; Webster and
Ricciardi, 1991). With only two notable exceptions, all
residues identified as essential for transcriptional activation
are conserved in the majority of E1A proteins. In the first
exception, the conservative substitution of leucine for valine
147 in HAdV-5 E1A (a.p. 202) abolishes transcriptional
activation (Webster and Ricciardi, 1991). However, the vast
majority of other E1A proteins contain a proline at this
position. The presence of proline at this position is likely
tolerated as the CR3 portion of HAdV-12 E1A strongly
activates early viral transcription (Ohshima and Shiroki,
1986). Structural analysis and peptide competition experi-
ments also fail to explain why substitution of leucine for
valine at position 147 was observed to have such a
Fig. 4. Analysis of functional conservation of residues within CR3 required for transcriptional activation. The percent identity of each adenoviral E1A sequence
to that of HAdV-5 was calculated for each position corresponding to residues 144 to 190 in HAdV-5 (alignment positions 199 to 245). HAdV-1, 2, and 6 E1A
were excluded as they are identical to HAdV-5 over this region. Residues previously identified by point-mutational analysis as critical for HAdV-5 E1A
transcriptional activation, interaction with TBP, interaction with Sur2 or promoter targeting are indicated as b+Q. Point mutants at each position have been tested
for all functions with the exception of Sur2 interaction. Question marks indicate residues that are essential for transcriptional activation, but their involvement in
TBP or Sur2 interaction is not clear. Asterisks indicate residues identified as critical for activity in HAdV-5 E1A that are not highly conserved. Black bars
indicate residues not known to be required for transcriptional activation, but for which only conservative substitutions have been tested that are often present at
the same alignment positions in the other E1A proteins. Hatched bars indicate highly conserved residues (N60% similarity) not required for transcriptional
activation. The position of the zinc finger and the two phosphorylated serines in HAdV-5 E1A are indicated.
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the second exception, substitution of an aspartic acid or
cysteine for glycine 180 (a.p. 235) seriously impairs trans-
activation by HAdV-5 E1A (Webster and Ricciardi, 1991),
but only the HAdV-40 and -41 E1A proteins contain glycine
at this position. Notably, all the subgroup B HAdV E1A
proteins contain a cysteine at this position, indicating that
they may be poor transcriptional activators. Substitution of
alanine or asparagine at position 180 in HAdV-5 E1A retains
function, suggesting that there is some flexibility in
composition at this location. Indeed, six of the other non-
subgroup C E1A proteins contain asparagines at this position.
Our analysis also shows that many residues not identified
as important for transcriptional activation by mutational
analysis are very highly conserved. For residues 144, 155,
156, 164, 168, 182, and 189 (a.p. 199, 210, 211, 219, 223,
237, 244; indicated as black bars in Fig. 4), only
conservative substitutions have been tested that are often
present at the same alignment positions in the other E1A
proteins. We would predict that non-conservative substitu-
tions at these positions will impair transcriptional activation.On the other hand, residues 152 and 153 (a.p. 207 and 208;
hatched bars in Fig. 4) are conserved in more than 60% of
the E1A sequences, although they have been conclusively
shown to be dispensable for transcriptional activation. This
suggests that they either play a role in another activity of
E1A or only influence transcriptional activation under
specific circumstances not yet tested in the laboratory.
CR3 can be subdivided into at least three functional
domains: a promoter targeting region, a TBP interaction
region and a Sur2/TRAP150h-binding region. In HAdV-5
E1A, residues 180–188 (a.p. 235–243) constitute a promoter
targeting region, which confers interaction with several
unrelated sequence specific transcription factors, including
ATF1-3, c-jun, SP1, USF, Oct-4, and CBF/NF-Y (Agoff and
Wu, 1994; Chatton et al., 1993; Liu and Green, 1990, 1994;
Scholer et al., 1991). It is difficult to imagine how this short
region of E1A makes specific contacts with such a diverse
range of unrelated transcription factors. Indeed, this region
of E1A also interacts with several TBP associated factors
(TAFs), including TAFII250, TAFII135, TAFII110, and
TAFII55 (Chiang and Roeder, 1995; Geisberg et al., 1995;
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selective transcriptional regulators via mechanisms that are
not yet fully defined. However, many are known to interact
with transcription factor activation domains, and all function
as components of multi-subunit protein complexes (Green,
2000). This raises the possibility that the promoter targeting
region of HAdV-5 E1A CR3 binds a single TAF directly,
which then indirectly mediates interaction with other TAFs
and specific classes of transcription factors. Regardless of
whether HAdV-5 E1A is recruited directly or indirectly by
specific DNA-binding transcription factors, this targeting is
normally necessary for transcriptional activation. However,
this region is not required for transcription if HAdV-5 E1A
is artificially tethered to a promoter by fusion to a
heterologous DNA-binding domain (Lillie and Green,
1989; Martin et al., 1990). Our analysis shows that the
carboxy-terminal portion of the promoter targeting region is
highly conserved in all the E1A proteins, indicating that
they each likely target the same cellular transcription
factors, be they DNA-binding proteins or TAFs.
Mutations in the CR3 promoter targeting region exhibit a
characteristic dominant negative effect on transcriptional
activation by wild-type HAdV-5 E1A, presumably by
sequestering limiting factors necessary for this activity
(Glenn and Ricciardi, 1987; Webster and Ricciardi, 1991).
The first of these to be identified was TBP (Lee et al., 1991).
Detailed analysis of the interaction of HAdV-5 E1A CR3
with TBP localized this interaction to residues 147, 150,
157, and 171 to 174 (a.p. 202, 205, 212 and 226–229),
which are in or around the zinc finger region (Geisberg et
al., 1994). With two notable exceptions, these residues are
well conserved. Firstly, the valine at position 147 (a.p. 202)
is only conserved in the subgroup C E1A proteins as
described above. Despite a proline at this position, which is
present in many of the other E1A proteins, HAdV-12 E1A
binds TBP very strongly in a CR3-dependent fashion
(Molloy et al., 1999). In the second exception, the E1A
proteins from subgroups D, E, and F contain a substitution
of alanine for serine at position 172 (a.p. 227), which
suggests that they will bind TBP poorly. It will be
interesting to compare the transcriptional activities of these
proteins and to determine the consequences of decreased, or
possibly increased, activity.
Although a clear relationship exists between the ability
of HAdV-5 E1A to bind TBP and activate transcription,
mutation of residues 148, 151, 154, 159, 161, 165, 169, 170
or 177 (a.p. 203, 206, 209, 214, 216, 220, 224, 225 and
232) blocks transcriptional activation despite retaining TBP
interaction (Geisberg et al., 1994). This observation
indicated that at least one other factor is essential for
transactivation by E1A, and ultimately led to the identi-
fication of the Sur2/TRAP150h component of the Media-
tor–TRAP complex as a target of the CR3 domain of
HAdV-5 E1A (Boyer et al., 1999; Wang and Berk, 2002).
Sur2 forms a subcomplex of the Mediator with Med/
TRAP100 and 95, and cells deficient in either Sur2 or Med/TRAP100 do not support transcriptional activation by
HAdV-5 E1A (Ito et al., 2002; Stevens et al., 2002).
Mutation of positions 154, 160, 171, 173, 175, 176, or 177
(a.p. 209, 215, 226, 228, 230, 231, and 232) blocks
association with Sur2 (Boyer et al., 1999), and these are
all highly conserved residues in the different E1A proteins.
Many of the mutants that fail to bind Sur2 retain TBP
binding, but fail to activate transcription, indicating that
Sur2 is one of the previously unknown key targets of CR3.
However, a class of mutants represented by positions 148,
151, 159, 161, 165, 169, and 170 (a.p. 203, 206, 214, 216,
220, 224, and 225) in HAdV-5 E1A are defective for
transcriptional activation (Martin et al., 1990) and remain
untested for interaction with Sur2 or TBP (Fig. 4). Thus,
there remains the exciting possibility that these residues
constitute a binding surface for yet another key factor
required for transcriptional activation.
Identification of highly conserved residues without known
function
As mentioned above, examination of the sequence
alignment indicates that a substantial number of highly
conserved amino acid residues within CR3 are required for
E1A function yet are not known to affect interaction with
any cellular protein. In addition, two residues within CR3
have been conclusively shown not to affect function, yet
remain highly conserved (Fig. 4). Close inspection reveals
that a similar situation exists throughout the entire E1A
alignment. Indeed, several absolutely conserved residues,
particularly within CR4, have neither known function nor
cellular target. Highly conserved residues that are not
known to be involved in any E1A function or protein
interaction are indicated in Figs. 2 and 3. They may
contribute to known protein interactions or functions of
E1A, or may represent key determinants of novel functions
that remain to be elucidated. Either possibility opens new
avenues of future investigation.Conclusions
The analyses presented here strengthen and refine the
positioning of the conserved regions within E1A. A
number of protein interaction motifs are unambiguously
present in many E1A species, suggesting a strong selective
pressure to maintain certain protein–protein interactions.
Despite the overall commonality of many of the interaction
motifs, our analysis reveals that clear differences exist
between many serotypes and the prototype HAdV-5 E1A.
Exploration of these differences will greatly expand our
understanding of the normal biological functions of E1A
and assist in the use of E1A as a tool to probe cellular
processes. In particular, this sequence alignment should aid
in the identification and precise definition of interaction
surfaces of E1A required for targeting cellular proteins.
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served subregions throughout the E1A proteins still do not
have identified functions. Discovery of their targets and
function remain promising areas of investigation. Further-
more, the detailed understanding of the structure–function
relationship in E1A is already being utilized in the
development of conditionally replicating HAdV-5 as
oncolytic agents (Fueyo et al., 2000, 2003; Gomez-
Manzano et al., 2004; Heise et al., 2000; Howe et al.,
2000). Our analysis will similarly allow exploitation of
other serotypes with altered specificity of infection or to
which pre-existing immunity is rare.Materials and methods
Provenance and propagation of virus
Viruses were obtained from the American Type Culture
Collection (Manassas, VA, USA), Dr. D. Erdman (Center
for Disease Control and Prevention, Atlanta, GA, USA) or
the Leiden University Medical Centre, Department of
Molecular Cell Biology virus collection (Leiden, The
Netherlands) as detailed in Table 1. Viruses were propagated
on monolayer cultures of A549 human lung epithelial
carcinoma cells.
Sequence determination and manipulation
Viral sequences were determined as described previously
(Avvakumov et al., 2002b). Briefly, mRNA was isolated
from A549 cells 6 h post-infection using Trizol (Invitrogen,
Burlington, ON, Canada) and used as a template for
Moloney murine leukemia virus reverse transcriptase
(Invitrogen) to generate total cDNA. The E1A gene was
then amplified with subgroup-specific primers designed to
anneal within highly conserved regions upstream and
downstream of the E1A coding region. PCR products were
subcloned into suitable vectors, and the E1A gene was
sequenced with vector-specific flanking primers. The newly
determined E1A sequences were deposited in GenBank and
their accession numbers are listed in Table 1.
Additional E1A sequences were obtained from Gen-
Bank and are also listed in Table 1. Alignment and
analysis of the largest predicted E1A proteins were
performed as before (Avvakumov et al., 2002b), using
CLUSTAL W (Thompson et al., 1994) with default
parameters except that the gap open cost was set to 2.
Alignments were edited manually using GeneDoc (Nich-
olas et al., 1997) and shaded to four levels of conservation
using the blosum 45 score table. The final alignment was
imported into the PHYLIP suite of software to calculate
phylogenetic distance using the programs PROTDIST.EXE
and NEIGHBOR.EXE (Dr. Joe Felsenstein, University of
Washington, Seattle, WA, USA) and visualized with Tree-
View (Page, 1996).Definition of conserved regions (CR)
To define the boundaries of the CRs precisely, a stringent
cutoff for each edge was adopted based on 100% identity or
similarity, with nine or fewer consecutive less conserved
residues occurring between absolutely conserved residues.
The average CR4 similarity between HAdV-5 E1A and all
other sequences, with the exception of the closely related
HAdV-1, 2, and 6, was calculated manually.Acknowledgments
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